<DOC>
	<DOCNO>NCT02410278</DOCNO>
	<brief_summary>The primary objective study evaluate whether montelukast reduce severity gastrointestinal ( GI ) event , measure Gastrointestinal Symptom Rating Scale ( GSRS ) , oral administration dimethyl fumarate ( DMF ) participant relapse form Multiple Sclerosis ( MS ) . The secondary objective study follow : To evaluate whether montelukast oral administration DMF participant relapse form MS decrease discontinuation due GI event reduce number participant take symptomatic therapy GI event ; To investigate effect montelukast incidence flush event oral administration 240 mg DMF participant relapse form MS .</brief_summary>
	<brief_title>Study Montelukast Gastrointestinal Tolerability Patients With Relapsing Forms Multiple Sclerosis Receiving Tecfidera</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Key Reside United States confirm diagnosis relapse form MS satisfy therapeutic indication describe local label As perceived Investigator , ability comply requirement study protocol operate eDiary require record GIrelated event Female subject childbearing potential surgically sterile must practice effective contraception participation study willing able continue contraception 30 day complete withdraw study . All men must practice effective contraception , donate sperm throughout study least 90 day last dose study treatment . Key History significant GI disease ( e.g. , irritable bowel disease , peptic ulcer disease , history major GI surgery , eosinophilic GI disease , food allergy ) Chronic use ( â‰¥7 consecutive day ) bismuth subsalicylate , simethicone , calcium carbonate , loperamide , protonpump inhibitor , ondansetron within 1 month prior Screening Visit Use follow medication : montelukast , immunotherapy , mast cell stabilizer , parenteral , inhaled , oral steroid 1 month prior Screening Visit . Use medication also permit duration study ( except use montelukast per study protocol ) lead discontinuation Have one major comorbidities , opinion Investigator , may affect outcome study History malignancy ( except basal cell carcinoma completely excise prior study entry ) , severe allergic anaphylactic reaction know drug hypersensitivity , abnormal laboratory result indicative significant disease , and/or major disease would preclude participation clinical study NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>